All In Biotech

Drug Trial Radar · NCT05442554

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

A Phase 4, Single Arm, Open Label, Multicenter Study of Brentuximab Vedotin Treatment of Chinese Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Nov 28, 2022

Primary completion

Aug 9, 2024

Study completion Aug 9, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.

Conditions

  • T-Cell Lymphoma

Interventions

  • Brentuximab vedotinDrug

    Brentuximab vedotin IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCLTime frame: Up to 58 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.